Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)’s share price was up 3.1% during mid-day trading on Friday . The company traded as high as $4.95 and last traded at $4.93, with a volume of 1,655,708 shares traded. The stock had previously closed at $4.78.

A number of equities analysts have issued reports on SGYP shares. Rodman & Renshaw reissued a “buy” rating and issued a $15.00 target price on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. BTIG Research reaffirmed a “buy” rating and set a $11.00 price target on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $13.00 price target on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. Zacks Investment Research raised Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Monday, May 16th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Synergy Pharmaceuticals in a report on Monday, May 9th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.37.

The company’s 50-day moving average price is $4.02 and its 200-day moving average price is $3.54. The company’s market cap is $895.44 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.03. Equities research analysts expect that Synergy Pharmaceuticals Inc. will post ($1.03) EPS for the current fiscal year.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.